Literature DB >> 16699603

Interrelations between psychiatric symptoms and drug-induced movement disorder.

Guy Chouinard1.   

Abstract

After 30 years of clinical research into drug-induced movement disorder (DIMD), we are still facing unresolved issues regarding the interrelations between psychiatric symptoms and DIMD. Recently, I proposed a new classification of DIMD that includes abnormal movements previously labelled extrapyramidal symptoms. DIMD caused by psychotropic drugs is still confused with psychiatric symptoms treated by the same drugs. The results from 2 international multicentre trials, the InterSePT and the Ris-Consta Studies, conducted in the era of both typical and atypical antipsychotic agents, which included over 3,000 patients with schizophrenia and schizoaffective disorder worldwide, still showed a high, but decreasing, incidence of pretreatment DIMD, which varied from 57.5% (1998-1999) to 47.4% (1999-2000), and a decreasing incidence of tardive dyskinesia, which varied from 12% (1998-1999) to 10.2% (1999-2000), reflecting the greater use of atypical antipsychotic drugs. Furthermore, in both studies, psychiatric symptoms as measured by the Positive and Negative Symptom Scale (PANSS) were significantly correlated with DIMD and DIMD subtypes, thus suggesting the need for additional measurement instruments in schizophrenia and related psychoses.

Entities:  

Mesh:

Year:  2006        PMID: 16699603      PMCID: PMC1449877     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  15 in total

1.  Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.

Authors:  John M Kane; Mariëlle Eerdekens; Jean-Pierre Lindenmayer; Samuel J Keith; Michael Lesem; Keith Karcher
Journal:  Am J Psychiatry       Date:  2003-06       Impact factor: 18.112

Review 2.  A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.

Authors:  Nadeem H Bhanji; Guy Chouinard; Howard C Margolese
Journal:  Eur Neuropsychopharmacol       Date:  2004-03       Impact factor: 4.600

3.  The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation.

Authors:  S R Kay; L A Opler; J P Lindenmayer
Journal:  Br J Psychiatry Suppl       Date:  1989-11

4.  Reliability and validity of the positive and negative syndrome scale for schizophrenics.

Authors:  S R Kay; L A Opler; J P Lindenmayer
Journal:  Psychiatry Res       Date:  1988-01       Impact factor: 3.222

5.  A rating scale for extrapyramidal side effects.

Authors:  G M Simpson; J W Angus
Journal:  Acta Psychiatr Scand Suppl       Date:  1970

6.  A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases.

Authors:  G Chouinard; L Annable; A Ross-Chouinard; P Mercier
Journal:  J Clin Psychopharmacol       Date:  1988-08       Impact factor: 3.153

Review 7.  Tardive dyskinesia: prevalence, incidence, and risk factors.

Authors:  J M Kane; M Woerner; J Lieberman
Journal:  J Clin Psychopharmacol       Date:  1988-08       Impact factor: 3.153

8.  The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

Authors:  S R Marder; J M Davis; G Chouinard
Journal:  J Clin Psychiatry       Date:  1997-12       Impact factor: 4.384

9.  The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients.

Authors:  Larry Alphs; Ravi Anand; M Zahur Islam; Herbert Y Meltzer; John M Kane; Ranga Krishnan; Alan I Green; Steven Potkin; Guy Chouinard; Jean-Pierre Lindenmayer; Rob Kerwin
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

10.  A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.

Authors:  H J Möller; H Müller; R L Borison; N R Schooler; G Chouinard
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

View more
  6 in total

1.  Anticholinergic use in children and adolescents after initiation of antipsychotic therapy.

Authors:  Irene Seunghyun Hong; Jeffrey R Bishop
Journal:  Ann Pharmacother       Date:  2010-06-29       Impact factor: 3.154

Review 2.  The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs.

Authors:  Guy Chouinard
Journal:  J Psychiatry Neurosci       Date:  2006-05       Impact factor: 6.186

Review 3.  Quantifying clinical relevance in the treatment of schizophrenia.

Authors:  Christoph U Correll; Taishiro Kishimoto; Jimmi Nielsen; John M Kane
Journal:  Clin Ther       Date:  2011-12       Impact factor: 3.393

4.  Decreased Gray Matter Volume of Cuneus and Lingual Gyrus in Schizophrenia Patients with Tardive Dyskinesia is Associated with Abnormal Involuntary Movement.

Authors:  Ting Yu; Yanli Li; Fengmei Fan; Hongbao Cao; Xingguang Luo; Shuping Tan; Fude Yang; Xiangyang Zhang; Yin Yao Shugart; L Elliot Hong; Chiang-Shan R Li; Yunlong Tan
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

5.  Extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate.

Authors:  Francois-Pierre Joubert; Bonginkosi Chiliza; Robin Emsley; Laila Asmal
Journal:  S Afr J Psychiatr       Date:  2021-01-11       Impact factor: 1.550

6.  Gray matter abnormalities in schizophrenia patients with tardive dyskinesia: a magnetic resonance imaging voxel-based morphometry study.

Authors:  Cheng-Ta Li; Kun-Hsien Chou; Tung-Ping Su; Chu-Chung Huang; Mu-Hong Chen; Ya-Mei Bai; Ching-Po Lin
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.